Highlights of This Issue 201

SPECIAL FEATURES

CCR Translations

203 Blinded by the Light: Molecular Imaging in Pancreatic Adenocarcinoma
Eric Collisson, and Margaret Tempero
See article p. 302

Molecular Pathways

206 Insulin Receptor Substrate Regulation of Phosphoinositol 3-Kinase
Heather E. Metz, and A. McGarry Houghton

212 Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
Thomas OHare, Michael W.N. Deininger, Christopher A. Eide, Tim Clackson, and Brian J. Druker

Review

222 Decreasing the Adverse Effects of Cancer Therapy: National Cancer Institute Guidance for the Clinical Development of Radiation Injury Mitigators

CANCER THERAPY: PRECLINICAL

275 Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of β-Lapachone for Pancreatic Cancer Therapy
Long Shan Li, Erik A. Bey, Ying Dong, Jieru Meng, Biswanath Patra, Carolyn P. Cooke, Li-E Wang, Victor G. Prieto, Jeffrey E. Gershewald, Qingyi Wei, and Elizabeth A. Grimm

HUMAN CANCER BIOLOGY

229 Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
Julie A. Ellerhorst, Victoria R. Greene, Suhendran Ekmecktzioglu, Carla L. Warneke, Marcella M. Johnson, Carolyn P. Cooke, Li-E Wang, Victor G. Prieto, Jeffrey E. Gershewald, Qingyi Wei, and Elizabeth A. Grimm
High Impact of Oatp1a/1b Transporters on In Vivo Disposition of the Hydrophobic Anticancer Drug Paclitaxel
Evita van de Steeg, Anita van Esch, Els Wagenaar, Cornelia M.M. van der Krujissen, Olaf van Tellingen, Kathryn E. Kenworthy, and Alfred H. Schinkel

IMAGING, DIAGNOSIS, PROGNOSIS

302 Plectin-1 as a Novel Biomarker for Pancreatic Cancer
Dirk Bausch, Stephanie Thomas, Mari Mino-Kenudson, Carlos Fernández-del Castillo, Todd W. Bauer, Mark Williams, Andrew L. Warshaw, Sarah P. Thayer, and Kimberly A. Kelly
See commentary p. 203

310 Fine-Needle Aspiration Biopsies for Gene Expression Ratio-Based Diagnostic and Prognostic Tests in Malignant Pleural Mesothelioma

317 A 4-Gene Signature Associated with Clinical Outcome in High-Grade Gliomas
Marie de Tayrac, Marc Aubry, Stephan Saikali, Amandine Eteheverry, Cyrille Surbled, Frédérique Guénolé, Marie-Dominique Galibert, Abderrahmane Hamlat, Thierry Lesimple, Véronique Quillien, Philippe Menei, and Jean Mosser

328 β-Catenin Activation Is Associated with Specific Clinical and Pathologic Characteristics and a Poor Outcome in Adrenocortical Carcinoma
Sébastien Gaujoux, Sophie Grabar, Martin Fassnacht, Bruno Ragazzon, Pierre Launay, Rossella Libè, Ilham Chokri, Anne Audebourg, Benedict Royer, Silviu Shiera, Marie-Cécile Vacher-Lavenu, Bertrand Dousset, Xavier Bertagna, Bruno Alloio, Jérôme Bertherat, and Frédérique Tissier

337 Circulating Tumor Cells and EpCAM Expression in Neuroendocrine Tumors
Mohid S. Khan, Theodora Tsigani, Mohammed Rashid, Jeremy S. Rabouhans, Dominic Yu, Tu Vinh Luong, Martyn Caplin, and Tim Meyer

CANCER THERAPY: CLINICAL

346 Primary CNS Lymphoma in Children and Adolescents: A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)
Oussama Abla, Sheila Weitzman, Jean-Yves Blay, Brian Patrick O’Neill, Lauren E. Abrey, Edward Neuwelt, Nancy D. Doolittle, Joachim Baehring, Kamlesh Pradhan, S. Eric Martin, Michael Guerera, Shafqat Shah, Hervé Chesonieres, Michael Silver, Rebecca A. Betensky, and Tracy Batchelor

353 Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study
Frederike K. Engels, Walter J. Loos, Jessica M. van der Bol, Peter de Bruijn, Ron H.J. Mathijsen, Jaap Verweij, and Ron A.A. Mathot

363 Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
Anthony W. Tolcher, Christopher J. Sweeney, Kyri Papadopoulos, Amita Patnaik, Elena G. Chioreau, Alain C. Mit, Kamalesh Sankhala, Eric Furfine, Jochem Gokemeijer, Lisa Iacono, Cheryl Eaton, Bruce A. Silver, and Monica Mit

372 Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer

382 EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients
Yu-Hong Li, Fang Wang, Lin Shen, Yan-Ming Deng, Qiong Shao, Fen Feng, Xin An, Feng-Hua Wang, Zhi-Qiang Wang, Rui-Hua Xu, and Jian-Yong Shao
ABOUT THE COVER

Immunofluorescence analysis demonstrating the cytoplasmic localization of galectin-3 in CD18/HPAF pancreatic cancer cells transfected with scramble control vector. The cells were grown at low density on sterile cover slips for 20 hours. After washing with 0.1 M HEPES-containing Hanks buffer, the cells were fixed in ice-cold methanol at -20°C for 2 minutes. After nonspecific blocking with 10% goat serum, cells were incubated with anti-galectin-3 antibody in PBS for 90 minutes at room temperature. Cells were washed 3 to 4 times with PBS containing 0.05% Tween-20 (PBS-T) and then incubated with FITC-conjugated anti-rat secondary antibodies for 60 minutes. The cells were counterstained with propidium iodide. Finally, slides were washed, mounted, and observed under a ZEISS confocal laser-scanning microscope. Photographs were digitally captured by using 510-software. For further details, please see Senapati and coworkers on page 267 in this issue.